[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497672":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":25,"armGroups":21,"interventions":21,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":60,"collaborators":21,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":21,"enrollmentInfo":72,"targetDuration":21,"studyType":75,"phases":21,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":42,"whyStopped":21,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":21},[9,13],{"measure":10,"description":11,"timeFrame":12},"changes in echocardiographic parameters (in patients receiving or not specific treatment)","variation in global longitudinal strain, diastolic parameters and degree of ventricular hypertrophy","6 months",{"measure":14,"description":15,"timeFrame":16},"cardiovascular outcomes","composite endpoint of death and heart failure hospitalization","24 months",[18],{"measure":19,"description":20,"timeFrame":16},"major cardiac arrhythmias","bradyarrhythmia, new-onset atrial fibrillation, ventricular tachycardia",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","CROSS_SECTIONAL","In the retrospective phase, patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Agostino Gemelli between January 2020 and November 2022 will be enrolled.\n\nIn the prospective phase, patients with the same features evaluated between December 2022 and December 2028.",[27],{"name":28,"affiliation":5,"role":29},"Francesca Graziani","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Francesca Graziani, MD","CONTACT","00390630154432","francesca.graziani@policlinicogemelli.it",{"name":37,"role":33,"phone":34,"phoneExt":21,"email":38},"maria chiara meucci, MD","mariachiara.meucci@guest.policlinicogemelli.it",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Fondazione Policlinico Gemelli IRCCS","RECRUITING","Roma","RM","00168","Italy","IT",{"type":49,"coordinates":50},"Point",[51,52],11.10642,44.99364,{"lat":52,"lon":51},[55,58],{"name":56,"role":33,"phone":57,"phoneExt":21,"email":35},"francesca graziani, MD","+31 3313957433",{"name":37,"role":33,"phone":59,"phoneExt":21,"email":38},"+ 31 3313957433",{"type":61,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100497672","echocardiographic-characterization-of-cardiac-amyloidosis-100497672",false,"NCT05760287","Echocardiographic Characterization of Cardiac Amyloidosis","Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study","Echo-AMY","Inclusion Criteria:\n\n* patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit.\n\nExclusion Criteria:\n\n* missing data\n* decline to the study participation","ALL","18 Years",{"count":73,"type":74},255,"ESTIMATED","OBSERVATIONAL","This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled.\n\nThe primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype.\n\nSecondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.",[78],"Cardiac Amyloidosis",[80,81],"echocardiography","left ventricle","2026-09-02",{"date":84,"type":85},"2026-09-04","ACTUAL",{"date":87,"type":85},"2022-12-09",{"date":89,"type":74},"2031-02-02",{"name":5,"class":6},1]